Sebelius Kathleen 4
4 · Humacyte, Inc. · Filed Sep 11, 2024
Insider Transaction Report
Form 4
Humacyte, Inc.HUMA
Sebelius Kathleen
Director
Transactions
- Sale
Common Stock
2024-09-10$5.39/sh−1,548$8,344→ 41,207 total - Exercise/Conversion
Stock Options (right to buy)
2024-09-10−2,479→ 6,021 totalExercise: $3.35From: 2024-08-15Exp: 2033-06-15→ Common Stock (2,479 underlying) - Exercise/Conversion
Common Stock
2024-09-10$4.34/sh+4,521$19,621→ 43,910 total - Exercise/Conversion
Stock Options (right to buy)
2024-09-10−4,521→ 3,979 totalExercise: $4.34From: 2024-08-09Exp: 2032-06-09→ Common Stock (4,521 underlying) - Exercise/Conversion
Common Stock
2024-09-10$3.35/sh+2,479$8,305→ 42,755 total - Sale
Common Stock
2024-09-10$5.41/sh−3,634$19,660→ 40,276 total
Footnotes (2)
- [F1]The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $5.411 to $5.42. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F2]The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $5.38 to $5.40. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.